The ability of abiraterone to improve the sensitivity of breast cancer cells to immune-mediated lysis was studied by Kwilas et al. [79] on two breast cancer cell lines: AR-positive luminal B (ZR75-1), and ER- and AR-negative mesenchymal stem-like cell lines (MDA-MB-231). Here, ESR1 is linked to breast carcinoma.